Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...